T. Rowe Price Associates
EIDX

T. Rowe Price Associates’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

T. Rowe Price Associates’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-211,102
Closed -$27.8M – 2896
2020
Q4 		$27.8M Buy
211,102
+345
+0.2% +$30.5K ﹤0.01% 1131
2020
Q3 		$10.7M Sell
210,757
-25,393
-11% -$1.14M ﹤0.01% 1289
2020
Q2 		$11.3M Buy
+236,150
New +$11M ﹤0.01% 1270

T. Rowe Price Associates's EIDX Position: Q1 2021 in Review

T. Rowe Price Associates sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 211,102 shares — an estimated $27.8M sold.

T. Rowe Price Associates first reported a position in EIDX in Q2 2020 and held it in 3 quarters. The position peaked at $27.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • T. Rowe Price Associates reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 211,102 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $27.8M.
  • T. Rowe Price Associates first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's Eidos Therapeutics, Inc. Common Stock position peaked at $27.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.